Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Itron enters its October 27 earnings window with a familiar tension: short interest remains high by any measure, yet the bears have been quietly trimming for weeks while the stock has lost nearly 12% over the past month.
The most interesting dynamic right now is that the price is falling while shorts are actually retreating. Short interest has dropped to 13.0% of the free float, from a recent peak above 13.5% in mid-September, with the past week alone seeing a 1.9% reduction in shares short. That is a meaningful pullback, but at nearly 5.8 million shares short and 13 days to cover (per the latest FINRA settlement data), the position is still substantial. The borrow market, however, offers no squeeze signal: availability is loose at 358%, meaning roughly three and a half shares are available to borrow for every one already short. Cost to borrow is just 0.51%, edging up 8% on the week but sitting near the bottom of its 30-day range. The ORTEX short score has also drifted lower this week, from 66.4 to 63.9, confirming the gradual unwind rather than any escalation. What this tells you is that the price weakness is not being driven by fresh short conviction. Something else is weighing on the stock.
Options positioning adds little urgency to that picture. The put/call ratio of 0.35 is almost exactly in line with its 20-day average of 0.34, with a z-score near zero. There is no unusual demand for downside protection and no meaningful call-side accumulation either. The market, at least through the options market, is treating this as a drift lower rather than a crisis.
The Street remains constructive, which makes the price action harder to explain away. All six analysts tracked carry buy-equivalent ratings, with a mean price target around $130, implying more than 50% upside to the current $85.58 close. The most recent action was Needham raising its target to $128 after the July print. Before that, TD Cowen cut from $145 to $130 in late April and JPMorgan trimmed from $133 to $113 around the same time, both keeping positive ratings. The direction of travel earlier in the year was target compression, and the stock has underperformed those revised expectations. The bull case rests on a utility capex cycle that supports mid-to-high single-digit revenue growth, record gross margins, and an Outcomes segment running at $95.9 million in revenue, up 22% year on year. The bear case flags a backlog that slipped from $4.5 billion to $4.4 billion, a back-end-loaded 2026, and free cash flow that came in well below consensus in Q1. The EV/EBITDA multiple has compressed by roughly 0.35 turns over 30 days to around 9.8x, and the P/E has shed nearly 1.8 points over the same period to 12.5x. That re-rating is visible in the price, yet analysts have not followed with fresh cuts.
One institutional detail worth noting is that Dimensional Fund Advisors added 232,190 shares in the most recent period, and First Trust added nearly 245,000. Those are among the larger reported moves. Soros Fund Management's reported stake also grew by 360,000 shares as of June. On the other side, the only open-market insider selling in the recent window came from the SVP of Device Solutions, who sold just under $937,000 in early September under a pre-arranged 10b5-1 plan, a scheduled sale rather than a discretionary read on the stock. The broader director share activity on October 1 was grant-type awards, not open-market purchases, so there is no insider buying signal here despite the surface appearance of multiple board members receiving shares.
Retail attention, for what it is worth, is running above its 90-day norm. The ORTEX alt data layer flags a Wikipedia views z-score near 2.0 as of late September, which places awareness at its highest in the recent window. There are no measured leading datasets for Itron's financials in the alt data coverage, so that attention signal is colour rather than prediction.
The last earnings print produced a 20.7% single-day gain and a 25.4% five-day move, while the result before that saw a 2.6% one-day drop. The October 27 print arrives with the stock down sharply from its post-July highs, shorts having trimmed but still substantial, and the Street uniformly positive on a widening gap to current prices. Whether the backlog stabilises and free cash flow recovers toward the $100 million-plus level the Street originally expected will determine whether that gap starts to close.
See the live data behind this article on ORTEX.
Open ITRI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
